71 results
8-K
EX-99.1
KANT
Kineta, Inc.
21 Mar 24
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
4:04pm
, underscoring the potential of KVA12123 as a next-generation immunotherapy. We truly appreciate the efforts of the healthcare professionals, the patients
8-K
EX-99.1
KANT
Kineta, Inc.
3 Oct 23
Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial
8:30am
of Kineta. “We appreciate the patients and healthcare providers that are participating in this important study, and we look forward to further evaluating
8-K
KANT
Kineta, Inc.
23 May 23
Kineta to Present at Jefferies Healthcare Conference
9:30am
Chief Executive Officer, Shawn Iadonato, Ph.D., will present at the Jefferies Healthcare Conference, to be held in New York, NY on June 7-9, 2023
8-K
EX-99.1
iu1p 6zksnupiq9g
23 May 23
Kineta to Present at Jefferies Healthcare Conference
9:30am
8-K
EX-99.1
s263vadopu 2c36
3 Apr 23
Kineta to Present at 22nd Annual Needham Healthcare Conference
7:01am
8-K
gx754xrd
3 Apr 23
Kineta to Present at 22nd Annual Needham Healthcare Conference
7:01am
8-K
EX-99.5
1c3ikkojixbfrokdam9
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
2yzhg2 lg9n8
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.6
hd97 vf83
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
424B3
i3jwo1 0zxgtmes9g
10 Nov 22
Prospectus supplement
4:21pm